{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:30:09Z","timestamp":1776796209720,"version":"3.51.2"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Hsiri Therapeutics Incorporated","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    The targeting of the mycobacterial electron transport chain for drug development has recently garnered significant clinical success. The cytochrome bcc complex within the electron transport chain has emerged as a viable drug target, with the antibiotic Q203 (Telacebec) showing excellent activity against\n                    <jats:italic>M. tuberculosis in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . To determine if Q203 can function as an antibiotic against the non-tuberculosis mycobacteria\n                    <jats:italic>M. avium<\/jats:italic>\n                    and\n                    <jats:italic>M. intracellulare<\/jats:italic>\n                    (MAC), MIC and bactericidal studies were performed, both against various laboratory and clinical strains of MAC as well as\n                    <jats:italic>in vivo<\/jats:italic>\n                    infection studies. These studies found that Q203 provides synergistic activity against all tested MAC isolates when combined with clarithromycin and provided significant added benefit in a acute\n                    <jats:italic>M. avium<\/jats:italic>\n                    mouse infection model when combined with clarithromycin and clofazimine.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0344608","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:34:28Z","timestamp":1776792868000},"page":"e0344608","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["QcrB inhibitor Q203 (Telacebec) can synergize with clofazimine and clarithromycin to control a Mycobacterium avium infection"],"prefix":"10.1371","volume":"21","author":[{"given":"Yong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Mulvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett C.","family":"Moraski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mizutare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-0651","authenticated-orcid":true,"given":"Jeffrey S.","family":"Schorey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"pone.0344608.ref001","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"CN Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0344608.ref002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/ijmr.IJMR_902_20","article-title":"Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases","volume":"152","author":"SK Sharma","year":"2020","journal-title":"Indian J Med Res"},{"issue":"3","key":"pone.0344608.ref003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1651491","article-title":"Epidemiology of Nontuberculous Mycobacteriosis","volume":"39","author":"J Adjemian","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"pone.0344608.ref004","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12879-024-09059-9","article-title":"Nontuberculous mycobacteria testing and culture positivity in the United States","volume":"24","author":"JE Marshall","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"2","key":"pone.0344608.ref005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2672.2009.04161.x","article-title":"Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment","volume":"107","author":"JO Falkinham","year":"2009","journal-title":"J Appl Microbiol"},{"key":"pone.0344608.ref006","doi-asserted-by":"crossref","first-page":"1394220","DOI":"10.3389\/fmicb.2024.1394220","article-title":"Treatment for non-tuberculous mycobacteria: challenges and prospects","volume":"15","author":"LE Conyers","year":"2024","journal-title":"Front Microbiol"},{"issue":"4","key":"pone.0344608.ref007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccm.2023.06.012","article-title":"Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease","volume":"44","author":"A Sawka","year":"2023","journal-title":"Clin Chest Med"},{"issue":"3","key":"pone.0344608.ref008","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1183\/13993003.00925-2015","article-title":"Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity","volume":"47","author":"MHC Slaats","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0344608.ref009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium Complex Pulmonary Disease","volume":"82","author":"YS Kwon","year":"2019","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"12","key":"pone.0344608.ref010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(24)00186-3","article-title":"Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial","volume":"12","author":"RL Goodall","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"9","key":"pone.0344608.ref011","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"K Pethe","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"pone.0344608.ref012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/13543784.2022.2030309","article-title":"Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB)","volume":"31","author":"BS Lee","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"pone.0344608.ref013","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1164\/rccm.202408-1632OC","article-title":"Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond","volume":"211","author":"S Janssen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"pone.0344608.ref014","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1128\/AAC.00618-16","article-title":"Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo","volume":"60","author":"GC Moraski","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0344608.ref015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1089\/mdr.2020.0239","article-title":"Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species","volume":"27","author":"J Wang","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"11","key":"pone.0344608.ref016","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/AAC.38.11.2521","article-title":"Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model","volume":"38","author":"B Ji","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0344608.ref017","article-title":"Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection","volume":"64","author":"J-P Lanoix","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0344608.ref018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00259-20","article-title":"Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model","volume":"64","author":"DV Almeida","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0344608.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007857","article-title":"Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses","volume":"14","author":"A Chauffour","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pone.0344608.ref020","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"SK Field","year":"2003","journal-title":"Chest"},{"issue":"4","key":"pone.0344608.ref021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection","volume":"152","author":"SL Martiniano","year":"2017","journal-title":"Chest"},{"key":"pone.0344608.ref022","article-title":"Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease","author":"WH Fares","year":"2025","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"11","key":"pone.0344608.ref023","doi-asserted-by":"crossref","first-page":"102823","DOI":"10.1016\/j.jiac.2025.102823","article-title":"Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease","volume":"31","author":"F Watanabe","year":"2025","journal-title":"J Infect Chemother"},{"issue":"1","key":"pone.0344608.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/19412711251370275","article-title":"Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease","volume":"39","author":"WH Fares","year":"2026","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"pone.0344608.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01853-24","article-title":"The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronic Mycobacterium avium lung infection","volume":"69","author":"B Rimal","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pone.0344608.ref026","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1021\/jm5003606","article-title":"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent","volume":"57","author":"S Kang","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0344608.ref027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"S Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"pone.0344608.ref028","doi-asserted-by":"crossref","first-page":"102327","DOI":"10.1016\/j.mib.2023.102327","article-title":"Inhibiting respiration as a novel antibiotic strategy","volume":"74","author":"BS Lee","year":"2023","journal-title":"Curr Opin Microbiol"},{"issue":"8","key":"pone.0344608.ref029","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/17460441.2023.2224553","article-title":"Novel targets and inhibitors of the Mycobacterium tuberculosis cytochrome bd oxidase to foster anti-tuberculosis drug discovery","volume":"18","author":"A Harikishore","year":"2023","journal-title":"Expert Opin Drug Discov"},{"issue":"28","key":"pone.0344608.ref030","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1073\/pnas.1706139114","article-title":"Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection","volume":"114","author":"NP Kalia","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0344608.ref031","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1038\/s41467-018-07804-8","article-title":"Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer","volume":"9","author":"N Scherr","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"pone.0344608.ref032","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acsinfecdis.9b00322","article-title":"Naturally-Occurring Polymorphisms in QcrB Are Responsible for Resistance to Telacebec in Mycobacterium abscessus","volume":"5","author":"R Sorayah","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"1","key":"pone.0344608.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227224","article-title":"Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds","volume":"15","author":"GC Moraski","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"pone.0344608.ref034","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00448-22","article-title":"Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis","volume":"66","author":"TQ Nguyen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0344608.ref035","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11102469","article-title":"Telacebec interferes with virulence lipid biosynthesis protein expression and sensitizes to other antibiotics","volume":"11","author":"Z Zhou","year":"2023","journal-title":"Microorganisms"},{"issue":"12","key":"pone.0344608.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00964-21","article-title":"The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus","volume":"65","author":"R Sorayah","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pone.0344608.ref037","doi-asserted-by":"crossref","first-page":"115539","DOI":"10.1016\/j.biopha.2023.115539","article-title":"Clofazimine: A journey of a drug","volume":"167","author":"J Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"pone.0344608.ref038","first-page":"296","article-title":"Chemotherapy of leprosy for control programs - WHO expert committee","volume":"7","author":"AC Mcdougall","year":"1992","journal-title":"Health Policy and Planning"},{"issue":"3","key":"pone.0344608.ref039","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche","volume":"4","author":"SA McGuffin","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"pone.0344608.ref040","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species","volume":"286","author":"T Yano","year":"2011","journal-title":"J Biol Chem"},{"issue":"12","key":"pone.0344608.ref041","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","article-title":"Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids","volume":"36","author":"CE Van Rensburg","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0344608.ref042","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"MC Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"pone.0344608.ref043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02637-16","article-title":"Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis","volume":"61","author":"J Jang","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:34:34Z","timestamp":1776792874000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344608"}},"subtitle":[],"editor":[{"given":"Selvakumar","family":"Subbian","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344608","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}